JOHN K. BUOLAMWINI, Ph.D.

Professor and Vice Chair
Pharmaceutical Sciences

Office: 327c Johnson Building
Tel: (901) 448-7533
jbuolamwini@uthsc.edu

Education

  • PostDoc, National Cancer Institute, NIH, Bethesda, MD, Cancer Molecular Pharmacology
  • PostDoc, Univeristy of Alberta, Canada, Biochemical Pharmacologyt
  • Ph.D., University of Alberta, Canada, Medicinal Chemistry
  • B.S., University of Science and Technology, Ghana, Pharmacy (B. Phatm. (honors)

Publications

  1. Gupte, A, Buolamwini, JK. Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorg Med Chem Lett, 19 (3), 917-21, 2009.
  2. Gupte, A, Buolamwini, JK. CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1). Bioorg Med Chem Lett, 19 (2), 314-8, 2009.
  3. Hevener, KE, Ball, DM, Buolamwini, JK, Lee, RE. Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents. Bioorg Med Chem, 16 (17), 8042-53, 2008.
  4. Zhu, Z, Buolamwini, JK. Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity. Bioorg Med Chem, 16 (7), 3848-65, 2008.
  5. Luo W, Liu J, Li J, Zhang D, Liu M, Addo JK, Patil S, Zhang L, Yu J, Buolamwini* JK, Chen* J, Huang* C. Anti-cancer Effects of JKA97 Are Associated with Its Induction of Cell Apoptosis via a Bax-dependent and p53-independent Pathway. Journal of Biological Chemistry, 283, 8624-8633, 2008.
  6. Gupte, A, Buolamwini, JK. Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitors. Bioorg Med Chem, 15 (24), 7726-37, 2007.
  7. Lin, W, Buolamwini, JK. Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. J Med Chem, 50 (16), 3906-20, 2007.
  8. Zhu, Z, Hofmann, PA, Buolamwini, JK. Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction. Am J Physiol Heart Circ Physiol, 292 (6), H2921-6, 2007.
  9. Patil, S, Kamath, S, Sanchez, T, Neamati, N, Schinazi, RF, Buolamwini, JK. Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorg Med Chem, 15 (3), 1212-28, 2007.
  10. Lin, W. and Buolamwini*, J. K. Synthesis, Flow Cytometric Evaluation and Identification of Highly Potent Dipyridamole Analogs as Equilibrative Nucleoside Transporter 1 (ENT1) Inhibitors. Bioorganic & medicinal chemistry, 50, 3906-3920, 2007.
  11. Patil, S., Kamath, S., Neamati, N and Buolamwini*, J. K. Synthesis and Biological Evaluation of Novel 5(H)-Phenanthridin-6-ones, 5(H)-Phenanthridin-6-one Diketoacid and Polycyclic Aromatic Diketoacid Analogs as New HIV-1 Integrase Inhibitors. Bioorganic & Medicinal Chemistry, 15, 1212-1228, 2007.
  12. Lin, W. and Buolamwini*, J. K. Synthesis, Flow Cytometric Evaluation and Identification of Highly Potent Dipyridamole Analogs as Equilibrative Nucleoside Transporter 1 (ENT1) Inhibitors. Journal of Medicinal Chemistry, 50, 3906-3920, 2007.
  13. Kamath, S, Buolamwini, JK. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev, 26 (5), 569-94, 2006.
  14. Patil S. and Buolamwini*, J. K. Recent Uses of Palladium Chemistry in Indole Synthesis. Curr. Organic Synthesis, 3, 477-498, 2006.
  15. Buolamwini, J. K. A Survey of Novel Anticancer Drug Targets. In Strategies for the Discovery and Clinical Testing of Novel Anticancer Agents (Adjei, A. A. and Buolamwini, J. K., eds.), Elsevier Health Science, 1-35, 2006.
  16. Zhu, Z., Hoffman, P. and Buolamwini*, J. K.. Cardioprotective effects of novel tetrahydroisoquinoline analogues of nitrobenzylmercaptopurine riboside in an Isolated Rat Heart Model. Am. J. Physiol. Heart and Circulation, 292 (6), H2921-6, 2006.
  17. Kamath, S. and Buolamwini*, J. K. Targeting EGFR and HER-2 Receptor Tyrosine Kinases for Cancer Drug Discovery and Development. Medicinal Research Reviews, 26 (5), 569-594, 2006.
  18. Gupte, A, Buolamwini, JK, Yadav, V, Chu, CK, Naguib, FN, el Kouni, MH. 6-Benzylthioinosine analogues: promising anti-toxoplasmic agents as inhibitors of the mammalian nucleoside transporter ENT1 (es). Biochem Pharmacol, 71 (1-2), 69-73, 2005.
  19. Kamath, SA, Buolamwini, JK. Asp746 to glycine change may have a greater influence than Cys751 to serine change in accounting for ligand selectivity between EGFR and HER-2 at the ATP site. J Comput Aided Mol Des, 19 (5), 287-91, 2005.
  20. Buolamwini, JK, Addo, J, Kamath, S, Patil, S, Mason, D, Ores, M. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr Cancer Drug Targets, 5 (1), 57-68, 2005.
  21. Ali-Osman, F., Friedman, H., Antoun, G., Reardon, D., Bigner, D., Buolamwini, J. K.. Rational Design and Development of Targeted Brain Tumor Therapeutics. in Brain Tumors (Ali-Osman, F., ed.), Humana Press, Totowa, NJ, 3-28, 2005.
  22. Thimmaiah, K. N., Easton, J. B., Germain, G. S., Morton, C. L., Kamath, S., Buolamwini, J. K. and Houghton, P. J. Identification of N10-Substituted Phenoxazines as Potent and Specific Inhibitors of Akt Signaling. Journal of biological chemistry, 280, 31924-35, 2005.
  23. Buolamwini*, J. K., Addo, J. K., Kamath, S., Patil, S., Mason, D. and Ores, M. Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents. Curr. Cancer Drug Targets, 5, 57-71, 2005.
  24. Gupte, A, Buolamwini, JK. Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitors. Bioorg Med Chem Lett, 14 (9), 2257-60, 2004.
  25. Addo, JK, Buolamwini, JK. Design, synthesis, and evaluation of 5'-S-aminoethyl-N(6)- azidobenzyl-5'-thioadenosine biotin conjugate: a bifunctional photoaffinity probe for the es nucleoside transporter. Bioconjug Chem, 15 (3), 536-40, 2004.
  26. Buolamwini*, J. K. and Ali-Osman, F.. Rational Design of Novel Anticancer Agents. In Brain Cancer Protocols (Ali-Osman, F., ed.), Humana Press, Totowa, NJ, In Press, 2004.
  27. Gupte, A. and Buolamwini*, J. K. Synthesis and Flow Cytometric Evaluation of Novel Halogen-Substituted Nitrobenzylthioinosine Analogs as es Transporter Inhibitors. Bioorg. Med. Chem. Lett, 14, 2257-2260, 2004.
  28. Kuo, C. L., Assefa, H., Saczewski, F., Brzozowski, Z., Kamath, S., Buolamwini*, J. K. and Neamati*, N.. Application of CoMFA and CoMSIA 3D-QSAR and Docking Studies in Optimization of Mercaptobenzenesulfonamides as HIV-1 Integrase Inhibitors. Journal of medicinal chemistry, 47, 385-399, 2004.
  29. Addo, J. K. and Buolamwini*. Synthesis and Evaluation of 5’-S-Aminoethyl-N6-azidobenzyl-5’-thioadenosine (SAEATA) Biotin Conjugate: A Bifunctional Photoaffinity Label for the Equilibrative Nitrobenzylthioinosine (NBMPR)-Sensitive (es) Nucleoside Transporter. Bioconjugate Chemistry, 15, 536-540, 2004.
  30. Kamath, S, Buolamwini, JK. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. J Med Chem, 46 (22), 4657-68, 2003.
  31. Assefa, H, Kamath, S, Buolamwini, JK. 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. J Comput Aided Mol Des, 17 (8), 475-93, 2003.
  32. Buolamwini, JK, Assefa, H. Overview of novel anticancer drug targets. Methods Mol Med, 85, 3-28, 2003.
  33. Zhu, Z, Furr, J, Buolamwini, JK. Synthesis and flow cytometric evaluation of novel 1,2,3,4-tetrahydroisoquinoline conformationally constrained analogues of nitrobenzylmercaptopurine riboside (NBMPR) designed for probing its conformation when bound to the es nucleoside transporter. J Med Chem, 46 (5), 831-7, 2003.
  34. Buolamwini, J. K.. A Survey of Novel Anticancer Molecular Targets. In Strategies for the Discovery and Clinical Testing of Novel Anticancer Drugs (Buolamwini, J.K. and Adjei, A.A., eds.), Humana Press, Totowa, NJ, 3-28, 2003.
  35. Assefa, H., Kamath, S. and Buolamwini*, J. K.. 3D-QSAR and Docking Studies on 4-Anilinoquinazoline and 4-Anilinoquinoline Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors. J. Comput.-Aided Mol. Design, 17, 475-493, 2003.
  36. Buolamwini, J. K. and Assefa, H.. Overview of Novel Anticancer Drug Targets. In Novel anticancer Drug Protocols, (Buolamwini, J.K. and Adjei, A.A., eds.), Humana Press, Totowa, NJ, 3-28, 2003.
  37. Kamath, S. and J. K. Buolamwini*. Receptor-Guided Alignment-Based Comparative 3D-QSAR Studies of Benzylidene Malonitrile Tyrphostins as EGFR And HER-2 Kinase Inhibitors. Journal of medicinal chemistry, 46, 4657-4668, 2003.
  38. Zhu, Z., Furr, J. and Buolamwini*, J. K. Synthesis and Flow Cytometric Evaluation of Novel 1,2,3,4-Tetrahydroisoquine Conformationally Constrained Analogues of Nitrobenzylmercaptopurine Riboside (NBMPR) Designed for Probing Its Bioactive Conformation When Bound to the es Nucleoside Transporter. Journal of medicinal chemistry, 46, 831-837, 2003.
  39. Buolamwini, JK, Assefa, H. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. J Med Chem, 45 (4), 841-52, 2002.
  40. Buolamwini, J. K.. Novel Molecular Targets for Cancer Drug Discovery. In The Molecular Basis of Human Cancer (Coleman W. B. and Tsongalis, G. J., eds.), Humana Press, Totowa, NJ, 521-540, 2002.
  41. Buolamwini*, J. K. and Assefa, H. CoMFA and CoMSIA 3D QSAR and Docking Studies on Conformationally-Restrained Cinnamoyl HIV-1 Integrase Inhibitors: Exploration of a Binding Mode at the Active Site. J. Med. Chem, 45, 841-852, 2002.
  42. Buolamwini, J. K. Cell Cycle Molecular Targets and Drug Discovery In Cell Cycle Checkpoints and Cancer, Editor: Blagosklonny M. V.. Landes Bioscience, 235-246, 2001.
  43. Bedir, E., Calis, I., Dunbar, C., Sharan, R., Buolamwini, J. K. and Khan, I. A. Two Novel Cycloartane-Type Triterpene Glycosides from the Roots of Astragalus prusianus. Tetrahedron, 57, 5961-5966, 2001.
  44. Wang, H., Prasad, G., Buolamwini, J. K. and Zhang, R. Antisense Anticancer Oligonucleotide Therapeutics. Curr. Cancer Drug Targets, 1, 177-196, 2001.
  45. Buolamwini, J. K.. Cell Cycle Molecular Targets in Novel Anticancer Drug Discovery. Curr. Pharm. Design, 6, 379-392, 2000.
  46. Buolamwini, J. K. and Ali-Osman, F. Dynamic Docking Study of 1-Chloro-2,4-dinitrobenzene (CDNB) Binding at the Putative H-Site of Human Glutathione-S-transferase Pi (GST-p) Polymorphic Proteins. In Biologically Active Natural Products: Pharmaceuticals (Cutler, H. and Cutler, S. J., eds.), CRC Press, Boca Raton, FL, 197-207, 2000.
  47. Weinstein, J. N. and Buolamwini, J. K.. Molecular Targets in Cancer Drug Discovery: Cell-Based Profiling. Curr. Pharm. Design, 6, 354-378, 2000.
  48. Raghavan, K., Parish, D., Khan, M. and Buolamwini, J. K. Building a Hypothesis for Nucleoside Transport Inhibitors. In Rational Drug Design (Parrill, A. L. and Reddy, M. R., eds.), American Chemical Society, Washington, D.C, 153-164, 1999.
  49. Buolamwini, J. K.. Novel Anticancer Drug Discovery. Curr. Opin. Chem. Biol, 3, 500- 509, 1999.
  50. Buolamwini, J. K.. Nucleoside Transport Inhibitors: Structure-Activity Relationships and Potential Therapeutic Applications. Curr. Med. Chem, 4, 35-66, 1997.
  51. Kombian, S. B., Saleh, T. M., Fiagbe, N. I. Y., Chen, X., Akabutu, J. J., Buolamwini, J. K. and Pittman, Q. J.. Ibogaine and a Total Alkaloidal Extract of Voacanga africana Modulate Neuronal Excitability and Synaptic Transmission in the Rat Parabrachial Nucleus In Vitro. Brain Res. Bullet, 44, 603-610, 1997.
  52. Ali-Osman, F., Akande, O., Xi-Mao, J. and Buolamwini, J. K.. Molecular Cloning, Characterization and Expression in Escherichia coli of Full-Length cDNAs of Three Human Glutathione S-Transferase-pi Gene Variants: Evidence for Differential Catalytic Activity of the Encoded Proteins. Journal of biological chemistry, 272, 10004-12, 1997.
  53. Zjawiony, J. K., Khalil, A. A., Clark, A. M., Hufford, C. D. and Buolamwini, J. K. Studies on Methylation in 7H-Naphtho[1,2,3 - i,j][2,7]naphthyridine-7-one System. Journal of heterocyclic chemistry, 34, 1233-1237, 1997.
  54. Rubinstein, L. V., Anderson, N. L., Buolamwini, J. K., van Osdol, W. W., Monks, A. P., Scudiero, D. A., Sausville, E. A., Zaharevitz, D. W., Bunow, B., Johnson, G. S., Wittes, R. E. and Paull, K. D. Weinstein, J. N., Myers, T., O’Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E. An Information-Intensive Approach to the Molecular Pharmacology of Cancer.. Science, 275, 343-349, 1997.
  55. Buolamwini*, J. K. and Joseph J. Barchi, Jr. Solution NMR Conformational Analysis of the Potent Equilibrative Sensitive (es) Nucleoside Transporter Inhibitor, S6-(4-Nitrobenzyl)mercaptopurine Riboside (NBMPR). Nucleosides and Nucleotides, 16, 2101-2110, 1997.
  56. Myers, T. G., Anderson, N. L., Waltham, M., Li, G., Buolamwini, J. K., Scudiero, D. A., Rubinstein, L. V., Paull, K. D., Sausville, E. A., and Weinstein, J. N. A Protein Expresssion Database for the Molecular Pharmacology of Cancer. Electrophoresis, 18, 647-653, 1997.
  57. Buolamwini, J. K., Raghavan, K., Pommier, Y., Kohn, K.W. and Weinstein, J. N.. Application of the Electrotopological State Index to QSAR Analysis of Flavone Derivatives as HIV-1 Integrase Inhibitors. Pharmceutical Research, 13, 1891-1894, 1996.
  58. Raghavan, K., Buolamwini, J. K., Pommier, Y., Kohn, K.W. and Weinstein, J. N.. Three Dimensional QSAR of HIV Integrase Inhibitors: A Comparative Molecular Field Analysis (CoMFA) Study. J. Med. Chem, 38, 890-897, 1995.
  59. Rubinstein, L. V., Koutsoukos, A. D., Monks, A. P., Scudiero, D. A., Anderson, N. L., Zaharevitz, D., Chabner, B. A., Grever, M. R. and Paull, K. D, van Osdol, W., Licht, J., Viswanadan, V. N. Kohn, K. W ,Weinstein, J. N., Myers, T., Buolamwini, J. K., Raghavan, K.. Predictive Statistics and Artificial Intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS. Stem Cells, 12, 13-22, 1994.
  60. Buolamwini, J. K., Wiley, J. S., Robins, M. J., Craik, J. D., Cass, C. E., Gati, W. P.; and Paterson, A. R. P.. Conjugates of fluorescein and SAENTA (5'-S-(2-aminoethyl)-N6-(4-nitrobenzyl)-5'-thioadenosine): Flow Cytometry Probes for the es Transporter Elements of the Plasma Membrane. Nucleosides and Nucleotides 13 (R. K. Robins Memorial Issue)., 737-751, 1994.
  61. Weinstein, J. N., Myers, T., Casciari, J. J., Buolamwini, J. K. and Raghavan, K. Neural Networks in the Biomedical Sciences: A Survey of 386 Publications since the Beginning of 1991. World Congress on Neural Networks, 2, 121-126, 1994.
  62. Jamieson, G.P., Brocklebank, A. M., Snook, M. B., Sawyer, W. H., Buolamwini, J. K., Paterson, A.R.P. and Wiley, J. S.. Flow Cytometric Quantitation of Equilibrative, Inhibitor-Sensitive Nucleoside Transporter Sites on Human Leukemic Cells. Cytometry, 14, 32-38, 1993.
  63. Buolamwini, J. K. and Knaus, E. E.. Synthesis and Antinociceptive Activity of 1-Methylpiperidylidene-2-(pyridine)sulfonamides and some Dihydropyridine Derivatives. European Journal of Medicinal Chemistry, 28, 447-453, 1993.
  64. Buolamwini, J. K. and Knaus, E. E.. Synthesis and Antinociceptive Activity of 3-Methyl Derivatives of 4-(Pyridyl) Isosteres of Meperidine. Drug Design Discovery, 8, 245-256, 1992.
  65. Buolamwini, J. K. and Knaus, E. E.. Synthesis and Antinociceptive Activity of 1-[2-(pyridyl)ethyl] and 1-[2-(dihydropyridyl)ethyl] Analogues of Fentanyl. Drug Design Discovery, 8, 307-312, 1992.
  66. Buolamwini, J. K. and Knaus, E. E. Synthesis and Analgesic Activity of 3-Methyl Derivatives of 4-(Pyridyl) Isosteres of Ketobemidone. European Journal of Medicinal Chemistry, 27, 81-86, 1992.
  67. Buolamwini, J. K. and Knaus, E. E. Synthesis and Antinociceptive Activity of 3-Methyl Derivatives of 4-(Pyridyl) Isosteres of Meperidine. Drug Design and Discovery, 8, 145-156, 1991.
  68. Buolamwini, J. K. and Knaus, E. E. Synthesis and Antinociceptive Activity of 4-Pyridyl and -Dihydropyridyl analogues of Meperidine and Ketobemidone. Drug Design and Delivery, 7, 19-31, 1990.
  69. Buolamwini, J. K. and Knaus, E. E.. Synthesis and Antinociceptive Activity of 7-Aryloxysulfonyl Piperidines. Drug Design and Delivery, 3, 35-47, 1988.